Use of Cidofovir for Recurrent Respiratory Papillomatosis

• Status: Completed
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Recurrent respiratory papillomatosis (RRP) is the most common benign neoplasm of the larynx in the pediatric population. The impact of the disease on patients and families can be tremendous due to the need for frequent treatment. It would be highly beneficial to develop effective medical therapies as adjunctive measures to surgical ablation with the goal of reducing the frequency of reoccurrence.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Wisconsin, Madison
• Treatments: Cidofovir

Criteria

Inclusion Criteria:

• 4 surgeries for RRP in last 12 months

Exclusion Criteria:

• Renal insufficiency

• Nephrotoxic drugs in the last 7 days

• Sulfa allergies

• Currently treated with systemic or topical HPV chemotherapeutic agents

• Females of childbearing potential with a positive pregnancy test

• Women who are breast feeding